Physician profile

Tara Zaabel

Family · Metairie, LA

NPI 1639678154

$229.33

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$91.04

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $108.59 2021
Avanir Pharmaceuticals, INC. $29.70 2022
Xeris Pharmaceuticals, INC. $19.24 2023 Gvoke Hypopen
Abbott Laboratories $19.11 2023 Freestyle Libre
Itamar Medical INC $18.83 2023 Watchpatone
Sumitomo Pharma America, INC. $18.57 2023 Gemtesa
Otsuka America Pharmaceutical, INC. $15.29 2023 Abilify Maintena, Rexulti

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Tara Zaabel

$229.33

in general payments reported 2019-2025

Years
2021-2023
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/11051701/tara-zaabel

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.